Overview

Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Status:
Recruiting
Trial end date:
2026-04-01
Target enrollment:
0
Participant gender:
Female
Summary
stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
The Netherlands Cancer Institute
Treatments:
Cisplatin
Criteria
Inclusion Criteria:

- candidate for primary CRS

- histological or cytological proven FIGO stage III primary epithelial ovarian,
fallopian tube, or extra-ovarian cancer

Exclusion Criteria:

- history of previous malignancies within 5 years prior to inclusion

- FIGO stage IV disease

- complete primary cytoreduction is impossible

- prior treatment for the current malignancy